A novel prognostic model integrating host vulnerability and tumor biology for elderly patients with diffuse large B-cell lymphoma: the BAMAL score

The BAMAL score is a novel, practical, and robust prognostic model for elderly DLBCL patients. It successfully integrates features of tumor biology with host-related vulnerability, providing superior predictive accuracy and clinical net benefit compared to standard indices. Crucially, the score offers actionable insights for decision-making: supporting the optimization of standard immunochemotherapy for intermediate-risk patients, while identifying high-risk patients for whom current cytotoxic regimens are futile, underscoring the urgent need for novel, chemotherapy-free therapeutic approaches.